Ignite Creation Date:
2024-05-05 @ 11:19 AM
Last Modification Date:
2024-10-26 @ 9:04 AM
Study NCT ID:
NCT00004912
Status:
COMPLETED
Last Update Posted:
2012-05-30
First Post:
2000-03-07
Brief Title:
Megestrol and Exercise in Treating Patients With Cancer-Related Weight Loss
Sponsor:
Northwestern University
Organization:
Northwestern University
Study Overview
Official Title:
Phase II Trial of Progressive Resistance Training With Megestrol Acetate for the Treatment of Cancer-Related Weight Loss
Status:
COMPLETED
Status Verified Date:
2012-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
RATIONALE Megestrol helps improve appetite Exercise may decrease cancer-related fatigue improve strength and build up lost muscle tissue Exercise plus megestrol may be effective treatment for cancer-related weight loss
PURPOSE Phase II trial to study the effectiveness of megestrol plus exercise to improve appetite increase strength gain lean body tissue and decrease fatigue in patients who have cancer-related weight loss
PURPOSE Phase II trial to study the effectiveness of megestrol plus exercise to improve appetite increase strength gain lean body tissue and decrease fatigue in patients who have cancer-related weight loss
Detailed Description:
OBJECTIVES I Determine the effect of megestrol and progressive resistance training on lean body mass total body weight functional capacity appetite and fatigue in patients with weight loss due to advanced malignancy
OUTLINE This is a multicenter study Patients receive oral megestrol once daily Patients also begin progressive resistance training 3 days a week Treatmentexercise continues for 12 weeks in the absence of unacceptable toxicity or progressive weight loss greater than 5 pounds or 5 or more over first 4 study weeks
PROJECTED ACCRUAL A total of 46 patients will be accrued for this study within 1 year
OUTLINE This is a multicenter study Patients receive oral megestrol once daily Patients also begin progressive resistance training 3 days a week Treatmentexercise continues for 12 weeks in the absence of unacceptable toxicity or progressive weight loss greater than 5 pounds or 5 or more over first 4 study weeks
PROJECTED ACCRUAL A total of 46 patients will be accrued for this study within 1 year
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| NCI-G00-1705 | None | None | None |
| NU-98CC6 | None | None | None |